PubRank

Steven Fishbane

Author PubWeight™ 52.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007 3.90
2 Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013 3.15
3 Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007 1.61
4 Hyponatremia in community-acquired pneumonia. Am J Nephrol 2007 1.59
5 Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008 1.54
6 Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int 2013 1.52
7 History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008 1.49
8 Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003 1.30
9 A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002 1.30
10 Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007 1.20
11 Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002 1.15
12 Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl 2002 1.15
13 Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003 1.11
14 Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Clin J Am Soc Nephrol 2008 1.06
15 Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol 2012 1.03
16 More on renal salt wasting without cerebral disease: response to saline infusion. Clin J Am Soc Nephrol 2009 1.01
17 Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006 0.98
18 Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 2004 0.96
19 Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant 2013 0.93
20 Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int 2008 0.92
21 Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther 2007 0.90
22 The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study. BMJ Open 2013 0.86
23 Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial 2008 0.84
24 Treating desmopressin-induced hyponatremia: a case using hypertonic saline. Clin Nephrol 2013 0.83
25 Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract 2007 0.83
26 How can erythropoietin requirements be reduced in dialysis patients? Semin Dial 2006 0.82
27 Cardiovascular risk evaluation before kidney transplantation. J Am Soc Nephrol 2005 0.82
28 CHOIR, CREATE, and anemia treatment in patients with CKD. Semin Dial 2007 0.81
29 Novel iron-based phosphate binders in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2015 0.79
30 Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. BMJ Open 2012 0.79
31 Peginesatide for anemia in chronic kidney disease. N Engl J Med 2013 0.79
32 Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex. Nat Clin Pract Nephrol 2006 0.79
33 The new label for erythropoiesis stimulating agents: the FDA'S sentence. Semin Dial 2012 0.79
34 Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure. Am J Nephrol 2007 0.78
35 Update on membranoproliferative GN. Clin J Am Soc Nephrol 2014 0.78
36 Hemoglobin variability: random fluctuation, epiphenomenon, or phenomenon? Semin Dial 2006 0.78
37 Pheochromocytoma multisystem crisis in a patient with multiple endocrine neoplasia type IIB and pyelonephritis. Am J Kidney Dis 2002 0.78
38 Safety issues with iron sucrose. Am J Kidney Dis 2003 0.78
39 Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia. Semin Nephrol 2002 0.78
40 The optimal hemoglobin in dialysis patients- a critical review. Semin Dial 2008 0.78
41 Longitudinal predictors of uremic pruritus. J Ren Nutr 2013 0.78
42 The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients. Hemodial Int 2005 0.77
43 How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. Semin Dial 2013 0.77
44 Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis catheters. Clin Nephrol 2012 0.77
45 The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial. J Ren Nutr 2013 0.77
46 Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. Am J Nephrol 2017 0.77
47 A physician's perseverance uncovers problems in a key nephrology study. Kidney Int 2012 0.76
48 Hepatic iron in hemodialysis patients. Kidney Int 2004 0.76
49 Dialysis: ESA responsiveness and outcomes in patients on hemodialysis. Nat Rev Nephrol 2011 0.75
50 Glomerular diseases: entering a new era. Clin J Am Soc Nephrol 2014 0.75
51 EPO adjuvant treatments: a need for more evidence. Am J Kidney Dis 2006 0.75
52 Nephrology Crossword: Onco-nephrology--chemotherapy agents and nephrotoxicity. Kidney Int 2013 0.75
53 How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis? Semin Dial 2006 0.75
54 Improving outcomes in late-stage kidney disease: the healthy transitions program. Nephrol News Issues 2014 0.75
55 Quality outcomes and obstacles to their achievement in end-stage renal disease. Semin Dial 2002 0.75
56 Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists. Ann Pharmacother 2009 0.75
57 The effect of hemodialysis ultrafiltration on changes in whole blood viscosity. Hemodial Int 2012 0.75
58 Forty-eight hour kidney transplant admissions. Clin Transplant 2013 0.75
59 Quality of reporting of randomization methodology in nephrology trials. Kidney Int 2012 0.75